FEB 2 3 2004

PTO/SB/21 (08-03)

Under the Panenwork Reduction Act of 1995, no nervou	Approved for use through 08/30/2003, OMB 0651-003* U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number									
OEMASK	Application Number	10/678,816								
TRANSMITTAL	Filing Date	October 2, 2003								
. FORM	First Named Inventor	Parry et al.								
(to be used for all correspondence after initial filing)	Art Unit	1652								
	Examiner Name	Not Yet Known								
Total Number of Pages in This Submission 3 w/refs	Attorney Docket Number	53038AUSM1								
ENCLOSURES (Check all that apply)										
Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request	Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Addr Terminal Disclaimer Request for Refund CD, Number of CD(s)	After Allowance communication to Technology Center (TC) Appeal Communication to Board of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please identify below): 1449 Form with references Return Post Card								
Firm or Wendy L. Washtien, Ph.D.	OF APPLICANT, ATTORN	EY, OR AGENT								
Individual name	·le¹.									
Weren C. Wwoo										
Date 345 19, 2004	- · · · <u></u>									
CERTIFIC	CATE OF TRANSMISSION	MAILING								
I hereby certify that this correspondence is being facs sufficient postage as first class mail in an envelope at the date shown below.	imile transmitted to the USPTO or idressed to: Commissioner for Pa	deposited with the United States Postal Service with tents, P.O. Box 1450, Alexandria, VA 22313-1450 on								
Typed or printed name Mary Ann Flores										
Signature Maux)	Jun Klares	Date Feb 19,2004								
This collection of information is required by 37 CFR 1.5. The i process) an application. Confidentiality is governed by 35 U.S	nformation is required to obtain or reta c.C. 122 and 37 CFR 1.14. This collect	in a benefit by the public which is to file (and by the USPTO to								

This collection of information is required by 37 CFR 1.9. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Parry et al.

Serial No. 10/678,816 : Group Art Unit: 1652

Filed October 2, 2003 : Examiner: Not yet known

For: Modified Hepsin Molecules Having a Substitute Activation Sequence and Uses

Thereof

Mail Stop Patent Application Commissioner for Patents Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

In accordance with 37 C.F.R. §1.56 and 1.97 through 1.98, Applicants wish to make known to the Patent and Trademark Office the references set forth on the attached form PTO-1449. As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. §1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Respectfully Submitted,

Wendy L. Washtien, Ph.D. (Reg. No. 36,301)

Patent Agent for Applicants

Date: 16 19, 7004

Berlex Biosciences 2600 Hilltop Drive P.O. Box 4099

Richmond, California 94806 Telephone No. 510-262-5411

Facsimile No.: 510-262-7095

FORM PTD-1449 (REV.7-80) FEB 2 3 2004 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE							APPLICATION NO. 10/678,816				
INFORMATION DISCLOSURE STATEMENT			APPLICANTS Parry et al.								
TRACTS e several sheets if necessary)				FILING DATE GROUP ART UNIT October 02, 2003 1652							
U.S. PATENT DOCUMENTS											
*EXAMINER INITIAL	DOCUMENT NUMBER DA			DATE	NAME	CLASS SUBCLASS		FILING DATE IF APPROPRIATE			
FOREIGN PATENT DOCUMENTS											
		DOCUMENT NUMBER	DATE		COUNTRY	TRANSLATION YES NO					
	1.	Leytus, Steven P. et al., "A Novel Trypsin-like Serine Protease (Hepsin) with a Putative Transmembrane Domain Expressed by Human Liver and Hepatoma Cells," <i>Biochemistry</i> , 27:1067-1074; 1988.									
	2.	Reveals a Serir	Somoza, John R. et al., "The Structure of the Extracellular Region of Human Hepsin Reveals a Serine Protease Domain and a Novel Scavenger Receptor Cysteine-Rich (SRCR) Domain," <i>Structure</i> , Vol. 11: 1123-1131; September 2003.								
	3.	Zhukov, Andrei et al., "Purification and Characterization of Hepsin From Rat Liver Microsomes", BBA, 1337: 85-95; 1997.									
EXAMINE	R				DATE CONSIDERED						
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).											

Forms/Pat/P7-27 [01/31/01]